RT Journal Article
SR Electronic
T1 Antiproliferative Effects of Gefitinib are Associated with Suppression of E2F-1 Expression and Telomerase Activity
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3387
OP 3391
VO 26
IS 5A
A1 MITSUHIRO SUENAGA
A1 AKIHIKO YAMAGUCHI
A1 HIROSHI SODA
A1 KOJI ORIHARA
A1 YUICHI TOKITO
A1 YOSHIMUNE SAKAKI
A1 MEGUMI UMEHARA
A1 KENJI TERASHI
A1 NAKAAKI KAWAMATA
A1 MIKIO OKA
A1 SHIGERU KOHNO
A1 CHUWA TEI
YR 2006
UL http://ar.iiarjournals.org/content/26/5A/3387.abstract
AB Background: Gefitinib (Iressa, ZD1839) is a selective epidermal growth factor receptor tyrosine kinase inhibitor. E2F-1 is a critical determinant in cell cycle. Growth signals up-regulate telomerase activity. The effects of gefitinib on E2F-1 and telomerase in A549, H23 and A431 cells were examined. Materials and Methods: Cell proliferation and cell cycle progression were measured by the WST-1 assay and flow cytometry. The expression of E2F-1 and cyclin-dependent kinase inhibitors was evaluated, and hTERT mRNA expression and telomerase activity were analyzed. Results: In the A431 and A549 cells, treatment with gefitinib inhibited cell proliferation and was associated with an increase in G1-phase. In both cell types, gefitinib decreased the expression of E2F-1 mRNA and protein, followed by the suppression of hTERT mRNA and telomerase activity. In the H23 cells, gefitinib did not affect cell proliferation. Conclusion: The antiproliferative effects of gefitinib may be, at least in part, due to the inhibition of E2F-1 expression and telomerase activity. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved